Suzhou RainMed Medical Technology Co., Ltd. (hereinafter referred to as "RainMed"), a vascular interventional surgery robot company, announced the completion of nearly $100 million series D financing led by Ping An Capital, the core private equity platform of China Ping An Group. Seresia Asset Management, Lighthouse Canton and other internationally renowned capital followed. This is after the completion of the series C financing of hundreds of millions of yuan led by the well-known institution Jinglin Asset, co-create Weiye and other shareholders, and the company has once again won the support and favor of top institutions.

This round of financing will be used to accelerate the clinical research and commercialization of caFFR and caIMR, support the continuous development of multiple product lines, and build the world's leading vascular interventional surgical robot. The continuous investment of well-known institutions, the rapid improvement of the company's valuation and the continuous enhancement of financial strength all pave the way for RainMed Medical to successfully access to the capital market. 

Mr. Lin Wang, Chief Investment Officer of Ping An Capital, said, "RainMed Medical focuses on the development of China's original and world-leading digital cardiovascular diagnosis and treatment technology, and the company's products have been applied in clinical practice on a large scale, which create great value. Ping An Group is the world's largest insurance group in terms of assets, with total assets exceeding 10 trillion yuan. It has a medical and health ecosystem covering 30 provinces, 21,000 medical institutions and more than 3,700 cooperative hospitals. It will actively support RainMed Medical to improve its commercial network and accelerate the application of its products in clinical practice. Ping An Capital is the core private equity investment platform of Ping An Group, and will continue to help RainMed Medical develop revolutionary diagnosis and treatment products for the benefit of domestic and overseas patients."

Mr. Cheng Kam Wah Conrad, CEO of Seresia Asset Management, said, "The original digital precision diagnostic product line of RainMed has been widely recognized by experts and scholars overseas for its evidence-based medicine evidence accumulated in many top medical centers at home and abroad. We believe that RainMed Medical will provide more efficient, convenient and innovative diagnosis and treatment services for patients in the future based on its strong scientific research and innovation ability and deep insight into the needs of doctors and patients."

Ms. Charlene Lin, co-founder of Lighthouse Canton, said: "We are very bullish on RainMed Medical 's strategic placement and product matrix. caFFR is the first Chinese original FFR product to achieve global sales. caIMR technology is also impressive, which is a blue ocean market with a scale of multi-billions. In addition, the vascular interventional surgical robot that the company is developing is still a new concept in Europe and America. I am very optimistic about the future development of this product and I believe that its research and development will greatly enhance the competitiveness of the company in the market."